ERBB2 and metastatic malignant neoplasm: By contrast, MIBC and carcinoma in situ exhibit deletions or mutations of TP53, RB transcriptional corepressor 1 (RB1), erb-b2 receptor tyrosine kinase 2 or PTEN, leading to metastatic cancer [27].